menu toggle

We Need to Make Biosimilars Easier to Get


Regarding Scott Gottlieb ’s “Don’t Give Up on Biosimilars—Congress Can Give Them a Boost” (op-ed, Aug. 26) and Peter B. Bach and Mark Trusheim’s “Time to Throw In the Towel on Biosimilars” (op-ed, Aug. 22): Eliminating rebates, which have turned the prescription-drug supply chain into a pay-to-play system, is a better way to create a robust supply of cheap biosimilar therapies than introducing price controls on older biologics. Biosimilar manufacturers that cannot afford to pay the hefty rebate payouts to pharmacy-benefit managers cannot access drug formularies even if their products are cheaper.

For the full article, visit The Wall Street Journal.